In a piece of research that was published on Monday, StockNews.com downgraded Innospec (NASDAQ: IOSP), moving the stock from a “strong-buy” rating to a “buy” rating for investors to consider investing in.
The most recent quarterly earnings report for Innospec (NASDAQ: IOSP) was made available to the general public on Tuesday, November 8th. The company that specializes in the production of specialty chemicals announced a quarterly profit of $1.74 per share, which is $0.34 more than the average prediction made by analysts, who anticipated the company would earn $1.40 per share. Even though market watchers anticipated that the company would bring in sales of $468.35 million during the quarter, the actual amount it brought in was $513 million. The return on equity for Innospec came in at 14.37%, while the company’s net margin came in at 7.04%. The current fiscal year of Innospec is expected to result in earnings of $6.26 per share. This is according to the projections of industry professionals.
SVP On Monday, December 5th, David B. Jones reportedly purchased 752 Innospec stock, as indicated by other departments’ disclosures. It costs $107.99 to purchase each share, bringing the total amount spent on acquiring stocks to $81,208.48. Because of the acquisition, the senior vice president now has direct ownership of 1,530 shares. This came about as a direct result of the acquisition. These shares are currently trading at a price corresponding to a market value of approximately $165,224.70. Follow the link, which will take you to a filing submitted to the Securities and Exchange Commission. In addition, you will have the opportunity to acquire additional information regarding the transaction. Currently, company insiders own 1.52 percent of the total shares outstanding.
The price of one share of Innospec increased by $1.72 during trading on Monday, bringing the company’s overall valuation to $104.78 per share. The usual volume of trading in the stock is 95,223 shares, so the amount of trading in the stock was significantly higher than usual at 130,993 shares. Both the price-to-earnings ratio and the beta value for the company come in at 1.16, with a price-to-earnings ratio of 19.92. The company’s total value, as measured by its market capitalization, is $2.59 billion. Over the previous twelve months, the price of Innospec ranged from a low of $83.13 to a high of $115.65. The company’s simple moving average over the past 50 days comes in at $103.07, while its simple moving average over the past 200 days comes in at $97.29.
In recent months, several institutional investors have modified their strategies to allocate their investments within the IOPS. During the first three months of 2018, Envestnet Asset Management Inc. increased the amount of Innospec stock owned by 15.4%, bringing the total to a 100% ownership percentage. Envestnet Asset Management Inc. now has a total of 4,397 shares of the specialty chemicals company’s stock following the purchase of an additional 586 shares during the most recent quarter. The company’s stock is currently valued at $407,000. The Teacher Retirement System of Texas increased the amount of Innospec stock owned by 7.3% over the first three months of 2018. The Texas Teacher Retirement System now owns 5,083 shares in the specialty chemicals business. This represents an increase of 346 shares since the end of the most recent quarter when the system made an additional purchase. The current price of the stock is calculated to be $470,000. Over the first three months of this year, the Swiss National Bank increased its holdings in Innospec by 7.2%. The Swiss National Bank now has 58,303 shares in the specialty chemicals company after purchasing an additional 3,900 shares during the most recent quarter for a total investment of 58,303. The value of these shares as of right now is $5,396,000 in total. During the first three months of 2018, Profund Advisors LLC grew its ownership of Innospec stock by 24.2%, bringing its total ownership to 100%. Following acquiring 666 shares during the most recent fiscal quarter, Profund Advisors LLC now holds 3,414 shares of the specialty chemicals company’s stock. This company’s stock is currently worth 316,000 dollars per share. In the first three months of 2018, JPMorgan Chase & Co. increased the number of Innospec stock owned by 7.4%, making this the last and most important point. After making an additional purchase of 7,181 shares during the most recent quarter, JPMorgan Chase & Co. now has a total of 104,796 shares of the specialty chemicals company’s stock in its possession. The price of one share of stock is currently $9,699,000. Institutional investors and hedge funds collectively hold a stake in the company equal to 96.42% of the total number of shares outstanding.
The production of specialty chemicals, as well as their blending, sale, and distribution in the United States of America, the rest of North America, the United Kingdom, and the rest of Europe, are all the responsibility of Innospec, Inc., in addition to their research and development. The Fuel Specialties division of the company offers its clientele a diverse range of specialty chemical compounds capable of performing the function of additives in several different types of fuel.